Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Pharmaco > Class 5- bipolar > Flashcards

Class 5- bipolar Flashcards

1
Q

Drugs and drugs that can precipitate a

manic episode

A

• Stimulants or hallucinogens
• Antidepressants
• Hormones
(synthroid, corticosteroids)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

MOOD STABILIZERS definition

A

Efficacy either in treating manic or depressive symptoms, without causing any switch of polarity (e.g. lamotrigine)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Li is a

A

Monovalent cation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Li

CLINICAL USE

A

o Bipolar disorder
o Schizo-affective disorder
o Major depressive disorder (adjunctive medication)
o Neutropenia secondary to clozapine (to increase
leukocytes)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Li Contraindications

A
  • Breastfeeding
  • Brain damage
  • Heart failure and other heart disease
  • Kidney failure
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Absorption Li

A

Good absorption through the gastrointestinal tract

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Distribution Li

A

Distributed in body water

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Metabolism Li

A

Not metabolized by the liver so no interaction with cytochrome

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Elimination Li

A

o Almost totally through the kidneys
o Large proportion is reabsorbed by the proximal tubule
o Elimination related to glomerular filtration rate
• Age
• Creatinine clearance

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Half-life time Li

A

o 8 to 35 hours (24h)

o Steady state reached in 5 days

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

DOSING Li

A

o Gradual increase
o Often administered BID to TID at the beginning of the treatment
• In order to reduce the “peaks” of plasma concentration
• Less GI side effects
o Adjust dose according to serum concentration
o Once the target dose is reached, lithium can be administered once daily (HS)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Therapeutic interval Li

A

0,6 – 1,2 mmol/L

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Therapeutic interval Li acute

A

0,8 – 1,2 mmol/L

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Therapeutic interval Li maintenance

A

0,6 – 1 mmol/L

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Therapeutic interval Li elderly

A

0,6 – 0,8 mmol/L

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Li, At steady state, when the dose is changed, the serum concentration should change ???

A

proportionally

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

LITHIUM CONCENTRATION IN BLOOD CELLS why use

A

Could potentially better predict the toxic effects of lithium

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

sign of intoxication Lithium in blood cells

A

> 0,6 mmol/L

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

STARTING LITHIUM

A
  1. Lithium 300 mg BID days 1 to 3
  2. Lithium 450 mg BID days 4 to 5
  3. Serum dose of lithium on the day 10 or 11
    • Steady state about 5 days after last dose increase
    • If < 0.6 mmol/L, increase the dose
    • If between 0.6 and 1.2 mmol/L, contrôle serum dosage within a week (if hospitalized) or in two weeks (if outpatient)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

MECHANISM OF ADVERSE EFFECTS Li

A

It replaces sodium (Na) in transmembrary

exchanges

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

SIDE EFFECTS Li

A 
v ACNE
- Up to 33% of patients
- Development or worsening of acne
v PSORIASIS
v ARRYTHMIAS
v CHANGES TO THE ECG, QTC PROLONGATION
- Especially in case of intoxication
v NAUSEA
- Especially at the beginning of treatment
v DRY MOUTH, THIRST
- Up to 75% of patients
v POLYURIA
- About 30% of patients
- Reduce serum lithium concentration
- Use once a day
- Investigating nephrogenic insipid diabetes
v KIDNEY DAMAGE
- Especially in case of intoxication
- In rarer cases: epithelial tubular damage, acute
tubular necrosis, nephrotic syndrome
v CHRONIC KIDNEY FAILURE?
- Gradually appears over the years
- Very rare end-stage kidney failure (0.2 to 1% of
patients receiving lithium for > 15 years)
v HYPOTHYROIDISM
- 8 - 19% of patients, may be irreversible
- Not a contraindication to start lithium
v HYPERPARATHYROIDISM
- Recommended basic calcium level, then tracked
- If hypercalcemia à PTH
v WEIGHT GAIN
- Especially at the beginning of treatment
- 4 -6 kg
v LEUKOCYTOSIS
- Often benign
v FINE TREMORS
- Related to blood concentration; reduce the dose
- Add propranolol 10 - 30 mg BID - TID
v OTHER CONCENTRATION-DEPENDANT EFFECTS
- Delirium, confusion, convulsions, coma
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

RISK FACTORS FOR DEVELOPING CHRONIC KIDNEY FAILURE on Li :

A
  • High lithium levels
  • Multiple lithium poisonings
  • Several takes a day (taking once a day, trough post 12 h isn’t at true lowest)
  • Concurrent medication (e.g. AINS, IECA/ARA, diuretics): all the ampril and sartan
  • Comorbidities (e.g. high blood pressure, diabetes)
  • Age
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Toxicity Li 1,5 – 2 mmol/L

A

Diarrhea, vomiting, drowsiness, muscle weakness,

decreased coordination

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Toxicity Li 2 – 2,5 mmol/L

A

Ataxia, blurred vision, ringing in the ears, change to the

ECG

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Toxicity Li> 3 mmol/L

A

Changes neurology, coma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Acute intoxication on chronic intoxication Li

A

= potentially fatal

Possible permanent neurotoxicity: memory impairment, ataxia, dysarthria and tremors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

TOXICITY

TREATMENT Li

A

o Stop lithium
o Gastric washing if lithium intake is recent
o Maintain volemia and electrolytes.
o Activated charcoal does not adsorb lithium, but can be administered if polyintoxication is suspected.
o Dialysis is effective and may be necessary for cases with target organ damage.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

↑ LITHIUM CONCENTRATION interaction

A
  • NSAID
  • Diuretics
  • Angiotensin Conversion Enzyme Inhibitors (IECA)
  • Angiotensin II receptor antagonists (ARA)
  • Alcohol (dehydrates)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

↓ LITHIUM CONCENTRATION interaction

A
  • Table salt

* Theophylline

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

PATIENT EDUCATION Li

A 
HE NEEDS TO KNOW THE INTERACTIONS
Products that stimulate urine production
Risk of dehydration
Drugs for pain (NSAID)
Acétaminophène (TylenolTM) is safe
Beware of medications used to treat cold
Some antihypertensives
Alcohol 
Always consult a health care professional before purchasing a new drug (prescription or over-thecounter)
Proper hydration
Diarrhea or vomiting=Rehydration STAT
Sweating (Heatwave, physical exercise)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

Before treatment protocol Li

A

o Recent physical examination
o FSC, urea, creatinine, electrolytes, calcium, TSH, urine analysis, b-hcg and fasting blood sugar, weight
o ECG if > 40 years old

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

During treatment protocol Li

A

o TSH q3 month x 2 years then q6 months
o Every year: FSC, urea, creatinine, electrolytes, total calcium, urine analysis, fasting blood sugar,
weight
o Vital signs at each serum dosage

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

FREQUENCY OF SERUM DOSAGE Li

A

-Initiation of treatment
• 1 to 2 times a week depending on the titration ad stabilization
• 1 to 2 times a month for a month
-Maintenance treatment
• q3 month x 2 years, q6 months thereafter
-In the following cases :
• prescription modification, addition of concurrent treatment, doubts about adherence, signs and
symptoms of toxicity, drug interactions or clinical situation warrants it

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

Valproic acid / Divalproex class

A

anticonvulsants

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

CLINICAL USE (MENTAL HEALTH) val

A

o Bipolar disorder
o Schizo-affective disorder
o Irritability, aggression, behavioural problems
o Intellectual disability

36
Q

Contraindications val

A
  • Pregnancy
  • Liver failure
  • Disorders of the urea cycle
37
Q

Absorption val

A

o Valproic acid is absorbed quickly
o Divalproex must dissolve, dissociate into valproic acid +
sodium valproate, which are absorbed

38
Q

Distribution val

A

o Very strong bond to plasma proteins

39
Q

Metabolism val

A

o Hepatic

40
Q

Half-time life val

A

o 9 to 19 hours

o Steady state reached in 5 days

41
Q

Loading dose val

A

o To achieve a therapeutic serum concentration faster

o 20 mg/kg

42
Q

Gradual titration val

A

oStarting dose : 500 – 750 mg / day

43
Q

Therapeutic interval : val

A

Ø 350 – 700 umol/L
Ø Therapeutic index wider than lithium
Ø Exact concentration not known for BD
** When you ask for a serum concentration of valproate, you immediately receive the TOTAL concentration (protein-bound + free fraction)

44
Q

PLASMA PROTEIN BINDING val

A

90 – 95 %: Concentration-dependent and saturable

FREE FRACTION: Active ingredient available to be active, be metabolized or eliminated

45
Q

TARGETED THERAPEUTIC INTERVAL OF FREE FRACTION val

A

35 – 70 umol/L

46
Q

Relevant laboratory in specific situations : val

A
  • Hypoalbuminemia, especially if < 30 g/L (e.g. malnourished patient)
  • Shifting binding sites
    Medical condition (e.g. liver or kidney disease)
    Drugs (e.g. phenytoin, high-dose aspirin)
47
Q

SIDE EFFECTS Val

A

v SKIN REACTIONS
- Rash
- Stevens-Johnson syndrome / toxic epidermal
necrosis (rare)
v ALOPECIA
- 6 – 24 %
- Concentration-dependent
- Zinc supplement or selenium could be beneficial?
v NAUSEA, VOMITING, DIARRHEA, CONSTIPATION
- Especially at the beginning of treatment, fade
over time
v HEPATOTOXICITY AND ↑ TRANSAMINASES
- Slight rise of transaminases
- Monitor liver transaminases and intervene if > 3 times normal
v PANCREATITIS
- 5 % of patients
- Stop valproate if necessary
v WEIGHT GAIN
- 50 % of patients
- 6 – 8 kg
v HYPERAMMONEMIA
- Altered state of consciousness, change in
behaviour, vomiting
- Especially if toxicity, high serum concentration
or drug interaction
- Light: reduce dose or suspend valproate
- Moderate - severe: L-carnitine or lactulose
v THROMBOCYTOPENIA
- 1 – 30 %
- Slight to moderate: valproate can be continued,
but closely monitored
-platelets less than 50 = stop epival
v ATAXIA
v DIPLOPIA
v DIZZINESS
v SEDATION
v TREMORS
- High-dose

48
Q

Toxicity val > 525 umol/L

A

Ataxia, fatigue, sedation, lethargy

* Possible tolerance (slow titration)

49
Q

Toxicity val> 700 umol/L

A

Tremors

50
Q

Toxicity val> 1200 umol/L

A

Stupor or coma

51
Q

PHARMACOKINETIC INTERACTIONS vAL

A

LAMOTRIGINE
• Divalproex increases lamotrigine serum concentration
• Risk of serious skin rash (e.g. Stevens- Johnson syndrome)
• Caution!!
HIGH-DOSE ASPIRIN
• Increases free fraction of divalproex by shifting the binding to plasma proteins
• High doses of ASA are rarely used in clinical practice

52
Q

Before treatment VAL

A 
o Recent physical examination
o FSC, liver function tests (AST, ALT, total bilirubin, alkaline phosphatase), fasting blood glucose, lipid profile, weight, waist circumference
oPregnancy test (if clinical indication)
53
Q

During treatment VAL

A

o FSC, liver function, weight and waist circumference q3 months x 1 year then each year
o Blood pressure, fasting blood glucose and lipid profile q6 months x 1 year then each year

54
Q

Carbamazépine class

A

anticonvulsants

55
Q

CLINICAL USE (MENTAL HEALTH) carb

A

o Type 1 and Type 2 BD

o Irritability, aggression, behavioural problems

56
Q

carb Contraindications

A

Bone marrow supression

57
Q

Metabolism carb

A

o Hepatic, via several cytochromes
o Enzymatic inductor
Ø Inductor of his own metabolism: ↑ dose = Induction it’s own metabolism= ↑ clearance = Steady state serum
concentration (2 – 3 weeks) = ↑ dose
Ø Many interactions with other drugs
o Toxic metabolite can accumulate and cause side effects

58
Q

Half-life time carb

A

25 – 65 hours

59
Q

Therapeutic interval :carb

A

17 – 54 umol/L

More frequent monitoring at the beginning of treatment (self-induction of the drug)

60
Q

SIDE EFFECTS carb

A
  • Rash
  • Stevens-Johnson syndrome / toxic epidermal
    necrosis (rare) especially in asians
    v NAUSEA
    v VOMITING
    v CONSTIPATION
    v DRY MOUTH
    v HYPONATREMIA
  • Ad 40 %
  • Possibly related to a SIADH
    v AGRANULOCYTOSIS / MEDULLARY APLASIA
  • Risk 5 to 8 x higher than the general population
  • Do not administer with clozapine
    v ATAXIA, DIZZINESS, DROWSINESS, TREMORS
  • Concentration-dependent
    v CONVULSIONS
  • Rare
61
Q

TOXICITY carb > 63 umol/L

A

Ataxia, nystagmus

62
Q

TOXICITY carb > 106 umol/L

A

Possibility of a pro-convulsive effect, coma

63
Q

Lamotrigine class

A

anticonvulsants

64
Q

Lamotrigine Clinical use (mental health)

A

o Treatment of depressive episodes
o Prevention depressive episodes
o Not effective in the treatment of mania

65
Q

POSOLOGY Lamotrigine

A

SLOW TITRATION
o To reduce the risk of Stevens-Johnson syndrome or toxic epidermal necrosis
o Reduce the speed of titration by 50% in the presence of valproate

66
Q

SIDE EFFECTS Lamotrigine

A 
v RASH
- About 7 %
v STEVENS-JOHNSON SYNDROME, TOXIC EPIDERMAL NECROSIS
- Rare
- Increased risk if fast titration
- Quickly stop lamotrigine
v NAUSEA
v VOMITING
v DIARRHEA
v ATAXIA
v DIZZINESS
v SEDATION
v DIPLOPIA
67
Q

PHARMACOKINETIC INTERACTIONS Lamotrigine

A

DIVALPROEX
• Divalproex increases serum lamotrigine
concentrations
• Risk of serious skin side effects (e.g. Stevens-Johnson syndrome)
• Caution!!
CONTRACEPTIVES
• Reduced serum lamotrigine concentration by 50%

68
Q

Several atypical antipsychotics are effective in BD for:

A

o Treatment of mania
o Treatment of depression
o Maintenance treatment
In BD with or without psychotic symptoms

69
Q

ATYPICAL ANTIPSYCHOTICS

Recommended as a first-line (CANMAT)

A

o Quétiapine in monotherapy or combination
o Asenapine in monotherapy or combination
o Aripiprazole in monotherapy or combination
o Palipéridone in monotherapy
o Risperidone in monotherapy or combination

70
Q

BEFORE INTRODUCING TREATMENT

A

ELIMINATE PRECIPITATING FACTORS
Substance-induced mania :
v Stop the substance or drug involved
v E.g. antidepressants, stimulants, drugs
v Limit caffeine/alcohol consumption
Mania induced by a medical condition (e.g. neurological condition)

71
Q

MONOTHERAPY OR COMBINATION?

Decision based on :

A

o The desired response time (e.g. combinations tend to work quickly)
o Patient history (e.g., partial prior response to monotherapy)
o Severity of the mania episode
o Concerns about the tolerability of a combination

72
Q

MONOTHERAPY

A

o Approximately 50% of patients will
respond to monotherapy in 3 to 4 weeks
o Comparable efficacy between different drugs

73
Q

COMBINATION

A

o Often the standard in the treatment of
bipolar affective disease (two poles to be
treated)
o About 20% more patients would respond to a combination

74
Q

EFFICACY

A

Therapeutic response expected in 1 to 2 weeks

75
Q

In the event of non-response or partial response to

treatment:

A

o Optimizing the dose
o Assess adherence to the drug
o Assess substance abuse

76
Q

In general, one of these drugs is used as a first-line treatment of mania:

A

q Lithium
q Valproate
q Atypical antipsychotic (e.g. quetiapine, aripiprazole, risperidone)
Monotherapy or combination

77
Q

If manic episode with psychotic features :

A

Prefer an antipsychotic
Often used: Li/DVP + antipsychotic
Benzodiazepines: Often used as adjuvants for restlessness, anxiety or insomnia. Caution in patients at risk of abuse

78
Q

ANTIDEPRESSANTS IN BD

A
  1. Avoid if antecedent of “switch” in mania on antidepressant
  2. Avoid during a mixed episode or during rapid cycling
  3. Use in monotherapy is not recommended for type 1 BD
    v Less clear evidence in type II BD
    v Less risk of ‘switch’, monotherapy possible for some antidepressants
    less risk for bupropion, zoloft
79
Q

In general, one of these drugs is used as a first-line treatment for bipolar depression:

A

q Quetiapine
q Lurasidone (alone or in combination)
q Lamotrigine (alone or in combination)
q Lithium

80
Q

the risk of relapse is higher within

A

2 to 4 months of the response to treatment,

81
Q

MAINTENANCE TREATMENT

A

Minimize the number of drugs
Use the smallest effective dose
Generally the same drug is targeted as acute treatment

82
Q

J.L. is a 74-year-old woman treated for bipolar disorder, hypertension, type II
diabetes and osteoarthritis. She is non-smoking and does not use alcohol or drugs. She is
currently receiving the following medications:
- lithium (Carbolith) 900 mg HS
- risperidone (Risperdal) 2 mg HS
- amlodipine (Norvasc) 5 mg DIE
- metformin (Glucophage) 500 mg BID
- glyburide (Diabeta) 5 mg DIE
She shows up for her monthly appointment at your clinic. On examination, you notice that she
has tremors and that she seems slightly confused. Her husband tells you that she presented
diarrhea in the last 2 days.
a) What do you think is the most likely cause of her symptoms?

A

Li toxicity

83
Q

J.L. is a 74-year-old woman treated for bipolar disorder, hypertension, type II
diabetes and osteoarthritis. She is non-smoking and does not use alcohol or drugs. She is
currently receiving the following medications:
- lithium (Carbolith) 900 mg HS
- risperidone (Risperdal) 2 mg HS
- amlodipine (Norvasc) 5 mg DIE
- metformin (Glucophage) 500 mg BID
- glyburide (Diabeta) 5 mg DIE
She shows up for her monthly appointment at your clinic. On examination, you notice that she
has tremors and that she seems slightly confused. Her husband tells you that she presented
diarrhea in the last 2 days.
In your questionnaire, you ask her if she has been taking her medication as prescribed in the
last few weeks and she answers you positively. She added that she went to the pharmacy to get
over-the-counter medications to treat her osteoarthritis. She can’t remember the name but
knows it’s an anti-inflammatory. She only took one tablet. How can this affect the patient’s drug
therapy?

A

Increase in Li concentration

84
Q

Topiramate pros and cons

A

1

85
Q

ECT which meds to stop

A

1

86
Q

Mr. SV has been taking risperidone 6 mg HS for the past year. His psychiatrist added
carbamazepine despite himself (not popular in psychiatry …) for relapse in manic episodes
requiring hospitalization. Treatment begins at 200 mg BID. The anxious psychiatrist prescribes
therapeutic monitoring of carbamazepine within a week. Result: 24 mmol/L (15-80 nmol/L).
Everyone is happy, the patient is discharged. Are you?

A

no steady state is only reached after 2-3 w

87
Q

Mr. PR was taking Divalproex 1000 mg HS, which has been increased to 1250 mg
HS recently. He’s been shaking for a few days. The serum dosage of Divalproex at steady state is
500 umol/L. What laboratory would it be appropriate to ask?

A

as for unbound

Pharmaco (11 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions